and buying a 3% for 7 years was the right call. I would be down tens of thousands right now. The fact that banks and reits are at 52 week lows should be creating shear panic. This is now the 4th downturn I have been through and I never got stuck. Old, retired, and watchful but never careless. I have given several warnings about getting out of the market with gains but???
Quad-Hope you sold at the top of the morning and are going to do it all over again. That's how you compound your profits.
I think it is a buyout candidite. I would look for a figure around 10 billion, maybe 12. I don't see anything in the teens anytime in 2016.
Someone popped in and started buying pretty aggressively, beginning around 2 p.m. If history is any guide, it could be the insider Bakers, further strengthening their already dominant position.
Hard to tell. Last time it was todays price was in April of 2014, it went down another 5 bucks a share in Jan. of last year to $30. Blue is down 10 bucks a share today and was a $197.00 a share stock last year down to $44.00 today. IBB down about $10. also. Bio does not look too good for 2016. If someone wanted to buy this out they would have bought in Jan. when it hit $30. They were not making a profit and had to do a secondary; those investors have also lost.
Here's a sure thing; it's down 8 bucks since your "conspiracy theory". If you loved it then at $45. you must be loading the boat at these bargain basement prices. Oh and that secondary? Why did they need it again?
Funny you mentioned CERS and the BB involvement. CERS shot up to $76.00 June 2001 and by Feb. 2003 it was $6.75. By 2004 it went to $2.00 and change. Now the share price is back to the 2003 price and pumpers are at it again. So you think Baker's held and watched this go down to the $2.00 level? They got out at the high and entered into more bio techs and the new pumps began. Trust me folks, they are taking profits from all which is the smart way to play this sector.
Being Opportunistic In The Market Sell-Off
• OCTOBER 7, 2015
• STEVEN BULWA
"It has been three and a half years since I wrote that Cerus was my stock pick for the next decade… The truth is things have developed pretty much as hoped and the company is on track to deliver the results I anticipated.
The company’s technology is used to clean transfusion blood of pathogens, increasing the supply of blood and making it safer. The technology has been approved in Europe for more than a decade and used without problem. In 2014 the company received U.S. approval for their plasma and platelet cleaning technology. Revenues are about to start to ramp from this approval. Revenues are estimated to grow over 40% next year to over $50 million.
The next big catalyst for the company is approval for the use of its technology on red blood cells. Based on a 2016 submission the company anticipates a possible CE mark for European approval in 2017. Approval in the United States would hopefully follow soon after. Given the FDA’s acceptance of plasma and platelet use based on European safety profile, I don’t foresee the same lengthy delay in receiving U.S. approval for red cells should Europe’s introduction be successful...
Because of share dilution I have to revise my price target down to $25-35/share, still a considerable return. This dilution has left the company with a strong balance sheet with over $120 million in cash."
****# 1 CERS shareholder is Baker Brothers!****
Baker Brothers are big holders of both CERS and SGEN ;-) Baker Brothers were also the # 1 shareholders of Avanir in 2014 (up 400%)!
Sentiment: Strong Buy